Yili Chuanning Biotechnology Co. Ltd. A
Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deace… Read more
Yili Chuanning Biotechnology Co. Ltd. A (301301) - Total Assets
Latest total assets as of June 2025: CN¥10.16 Billion CNY
Based on the latest financial reports, Yili Chuanning Biotechnology Co. Ltd. A (301301) holds total assets worth CN¥10.16 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Yili Chuanning Biotechnology Co. Ltd. A - Total Assets Trend (2021–2024)
This chart illustrates how Yili Chuanning Biotechnology Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Yili Chuanning Biotechnology Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Yili Chuanning Biotechnology Co. Ltd. A's total assets of CN¥10.16 Billion consist of 39.3% current assets and 60.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 10.3% |
| Accounts Receivable | CN¥939.30 Million | 8.9% |
| Inventory | CN¥1.34 Billion | 12.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥235.83 Million | 2.2% |
| Goodwill | CN¥1.37 Million | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Yili Chuanning Biotechnology Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Yili Chuanning Biotechnology Co. Ltd. A's current assets represent 39.3% of total assets in 2024, an increase from 34.0% in 2021.
- Cash Position: Cash and equivalents constituted 10.3% of total assets in 2024, up from 5.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, unchanged from 2.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 12.7% of total assets.
Yili Chuanning Biotechnology Co. Ltd. A Competitors by Total Assets
Key competitors of Yili Chuanning Biotechnology Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Yili Chuanning Biotechnology Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Yili Chuanning Biotechnology Co. Ltd. A generates 0.55x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Yili Chuanning Biotechnology Co. Ltd. A generates $ 13.27 in net profit.
Yili Chuanning Biotechnology Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.16 | 1.92 | 1.92 |
| Quick Ratio | 1.56 | 1.49 | 1.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.11 Billion | CN¥ 1.96 Billion | CN¥ 1.96 Billion |
Yili Chuanning Biotechnology Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Yili Chuanning Biotechnology Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.07 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 4.1% |
| Total Assets | CN¥10.55 Billion |
| Market Capitalization | $731.85 Million USD |
Valuation Analysis
Below Book Valuation: The market values Yili Chuanning Biotechnology Co. Ltd. A's assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Yili Chuanning Biotechnology Co. Ltd. A's assets grew by 4.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Yili Chuanning Biotechnology Co. Ltd. A (2021–2024)
The table below shows the annual total assets of Yili Chuanning Biotechnology Co. Ltd. A from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥10.55 Billion | +4.09% |
| 2023-12-31 | CN¥10.14 Billion | -2.42% |
| 2022-12-31 | CN¥10.39 Billion | +9.82% |
| 2021-12-31 | CN¥9.46 Billion | -- |